title: [Impact of coronary sirolimus-eluting stents on long-term outcome in diabetic patients].
abstract: OBJECTIVE
  To analyse the impact of sirolimus-eluting stents (SES) on long-term outcomes in patients with coronary artery disease (CAD) and diabetes.
  
  
  METHODS
  Among 1004 patients with CAD undergone percutaneous coronary intervention (PCI), 84 diabetic and 250 non-diabetic patients received SES, 168 diabetic and 502 non-diabetic patients had bare metal stent (BMS) implantation. Baseline clinical characteristics, interventional procedures (coronary angiography and PCI), occurrence of major adverse cardiac events (MACE), and MACE-free survival rates at one year during follow-up were compared.
  
  
  RESULTS
  During follow-up (average 16.2 months), patients (with and without diabetes mellitus) who received SES had similar occurrence of MACE (4.8% vs. 3.6%, P = 0.744) and MACE-free survival rates at one year (95.0% vs. 96.7%, P = 0.602). However those received BMS had a higher occurrence of MACE in diabetes mellitus than that in non-diabetic patients (31.0% vs. 21.7%, P = 0.015). MACE-free survival rate at one year was lower in diabetic patients with BMS than that in non-diabetic patients with BMS (74.2% vs. 86.8%, P = 0.001).
  
  
  CONCLUSIONS
  Implantation of sirolimus-eluting stents may reduce the major adverse cardiac events and the frequency of repeat intervention in patients with diabetes mellitus.
authors.affiliation: Department of Cardiology, Ruijin Hospital, Shanghai Second Medical University, Shanghai 200025, China.
authors.forename: Yue-hua
authors.initials: YH
authors.lastname: Fang
authors.forename: Wei-feng
authors.initials: WF
authors.lastname: Shen
authors.forename: Rui-yan
authors.initials: RY
authors.lastname: Zhang
authors.forename: Jian-sheng
authors.initials: JS
authors.lastname: Zhang
mesh_terms: D003327:Coronary Disease / Q000628:therapy*; D003925:Diabetic Angiopathies / Q000628:therapy*; D005260:Female; D006801:Humans; D008297:Male; D012189:Retrospective Studies; D020123:Sirolimus / Q000008:administration & dosage*; D015607:Stents
chemical_list: D020123:Sirolimus